XML 179 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
Commitments and Contingencies (Details) - USD ($)
 12 Months Ended
Jun. 01, 2023
Dec. 31, 2023
Dec. 11, 2023
Dec. 01, 2023
Other Commitments [Line Items]        
License consideration paid   $ 250,000    
Milestone payments due, description   (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of U.S. Food and Drug Administration (“FDA”) marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company’s product candidate reaching $250 million in cumulative sales.    
Aggregate amount       $ 49,272,323
Unpaid service fee $ 793,112.46      
Total amount     $ 1,007,700.5